MCID: PRR004
MIFTS: 39

Preretinal Fibrosis

Categories: Eye diseases

Aliases & Classifications for Preretinal Fibrosis

MalaCards integrated aliases for Preretinal Fibrosis:

Name: Preretinal Fibrosis 12 15
Macular Puckering of Retina 12
Macular Retinal Puckering 12
Cellophane Maculopathy 12
Epiretinal Membrane 43

Classifications:



External Ids:

Disease Ontology 12 DOID:2006
ICD9CM 34 362.56
MeSH 43 D019773
SNOMED-CT 67 53428005 55991001
UMLS 71 C0339543

Summaries for Preretinal Fibrosis

MalaCards based summary : Preretinal Fibrosis, also known as macular puckering of retina, is related to vitreoretinopathy, neovascular inflammatory and microvascular complications of diabetes 5. An important gene associated with Preretinal Fibrosis is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and PI3K-Akt signaling pathway. The drugs Nepafenac and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are cardiovascular system and growth/size/body region

Related Diseases for Preretinal Fibrosis

Diseases related to Preretinal Fibrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 148)
# Related Disease Score Top Affiliating Genes
1 vitreoretinopathy, neovascular inflammatory 31.3 VEGFA TGFB2 RLBP1 HGF GFAP FN1
2 microvascular complications of diabetes 5 31.0 VEGFA TGFB2 ANGPT2
3 vitreous detachment 31.0 VEGFA FN1 DPT
4 macular holes 30.8 VEGFA TGFB2 FN1 ANGPT2
5 kuhnt-junius degeneration 30.4 VEGFA ANGPT2
6 retinal vascular disease 30.3 VEGFA FN1 ANGPT2
7 retinal perforation 30.0 VEGFA RLBP1 FN1
8 macular retinal edema 29.9 VEGFA ANGPT2
9 macular degeneration, age-related, 1 29.9 VEGFA RLBP1 GFAP FN1 FLVCR1
10 exudative vitreoretinopathy 1 29.8 VEGFA FN1 ANGPT2
11 eye disease 29.8 VEGFA TGFB2 RLBP1 GFAP FN1
12 capillary hemangioma 29.7 VEGFA ANGPT2
13 microvascular complications of diabetes 1 29.7 VEGFA TGFB2 HGF GFAP ANGPT2
14 retinitis pigmentosa 29.2 VEGFA RLBP1 KIZ GFAP FN1 FLVCR1
15 retinal detachment 10.9
16 microvascular complications of diabetes 2 10.8
17 vitreoretinopathy 10.8
18 cataract 10.8
19 retinal disease 10.6
20 uveitis 10.6
21 refractive error 10.5
22 aniseikonia 10.5
23 myopia 10.4
24 coats disease 10.4
25 neuroretinitis 10.4
26 congenital heart defects, hamartomas of tongue, and polysyndactyly 10.4
27 retinitis 10.4
28 diabetic macular edema 10.4
29 scotoma 10.4
30 combined hamartoma of the retina and retinal pigment epithelium 10.4
31 retinal vein occlusion 10.3
32 astigmatism 10.3
33 endophthalmitis 10.3
34 intraocular pressure quantitative trait locus 10.3
35 optic nerve disease 10.3
36 fibrosis of extraocular muscles, congenital, 1 10.2
37 neurofibromatosis, type iv, of riccardi 10.2
38 strabismus 10.2
39 pars planitis 10.2
40 open-angle glaucoma 10.2
41 hemangioma 10.2
42 ocular hypertension 10.2
43 mechanical strabismus 10.2
44 47,xyy 10.2
45 eales disease 10.2
46 pik3ca-related overgrowth syndrome 10.2
47 blood group, globoside system 10.2 VEGFA FN1
48 neovascular glaucoma 10.2 VEGFA TGFB2
49 decubitus ulcer 10.2 VEGFA FN1
50 basal cell nevus syndrome 10.1

Graphical network of the top 20 diseases related to Preretinal Fibrosis:



Diseases related to Preretinal Fibrosis

Symptoms & Phenotypes for Preretinal Fibrosis

MGI Mouse Phenotypes related to Preretinal Fibrosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.87 ANGPT2 FLVCR1 FN1 GFAP HGF TGFB2
2 growth/size/body region MP:0005378 9.76 DPT FLVCR1 FN1 GFAP HGF RLBP1
3 craniofacial MP:0005382 9.65 FLVCR1 FN1 RLBP1 TGFB2 VEGFA
4 integument MP:0010771 9.43 ANGPT2 DPT FLVCR1 FN1 RLBP1 VEGFA
5 vision/eye MP:0005391 9.1 ANGPT2 DPT GFAP RLBP1 TGFB2 VEGFA

Drugs & Therapeutics for Preretinal Fibrosis

Drugs for Preretinal Fibrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
2
Bevacizumab Approved, Investigational Phase 4 216974-75-3
3
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
4
Ranibizumab Approved Phase 4 347396-82-1 459903
5
Verteporfin Approved, Investigational Phase 4 129497-78-5
6
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
7
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
8
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
9
Polyestradiol phosphate Approved Phase 4 28014-46-2
10
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
11 Antineoplastic Agents, Immunological Phase 4
12 Anti-Infective Agents Phase 4
13 Angiogenesis Inhibitors Phase 4
14 Photosensitizing Agents Phase 4
15 Norgestimate, ethinyl estradiol drug combination Phase 4
16 Contraceptive Agents Phase 4
17 Estradiol 17 beta-cypionate Phase 4
18 Topoisomerase Inhibitors Phase 4
19 Contraceptives, Oral, Combined Phase 4
20 Contraceptives, Oral Phase 4
21 Anti-Bacterial Agents Phase 4
22 Estradiol 3-benzoate Phase 4
23
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
24
Dinoprostone Approved Phase 3 363-24-6 5280360
25
Diclofenac Approved, Vet_approved Phase 3 15307-86-5 3033
26
Indomethacin Approved, Investigational Phase 3 53-86-1 3715
27
Bromfenac Approved Phase 3 91714-94-2 60726
28
Infliximab Approved Phase 3 170277-31-3
29
Lutein Approved, Investigational, Nutraceutical Phase 3 127-40-2 6433159
30 Anti-Inflammatory Agents Phase 3
31 Analgesics, Non-Narcotic Phase 3
32 Anti-Inflammatory Agents, Non-Steroidal Phase 3
33 Analgesics Phase 3
34 Cyclooxygenase Inhibitors Phase 3
35 Ophthalmic Solutions Phase 3
36 Tocolytic Agents Phase 3
37 Lubricant Eye Drops Phase 3
38 Gastrointestinal Agents Phase 3
39 Antirheumatic Agents Phase 3
40 Pharmaceutical Solutions Phase 3
41 Dermatologic Agents Phase 3
42
Vitamin A Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
43 retinol Phase 1, Phase 2
44 Retinol palmitate Phase 1, Phase 2
45
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 5743
46
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1 1177-87-3
47
Celecoxib Approved, Investigational Phase 1 169590-42-5 2662
48 Dexamethasone 21-phosphate Phase 1
49 Antiemetics Phase 1
50 HIV Protease Inhibitors Phase 1

Interventional clinical trials:

(show top 50) (show all 104)
# Name Status NCT ID Phase Drugs
1 Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery Completed NCT00818844 Phase 4 Nepafenac 0.1%
2 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study) Completed NCT01613716 Phase 4 Ozurdex
3 Determining the Effect of Low-dose Isotretinoin on Proliferative Vitreoretinopathy Completed NCT01445028 Phase 4 Isotretinoin
4 Intravitreal Alflibercept Injection (IAI) for Persistent Diabetic Macular Edema (DME) After Treatment With Bevacizumab And Ranibizumab Completed NCT03340610 Phase 4 Alflibercept
5 Cohort Study of the Clinical Course of Macular Diseases in Kagawa (Kagawa Macula Cohort Study) Recruiting NCT02321267 Phase 4 ranibizumab, aflibercept, pegaptanib, verteporphin
6 Evaluation and Comparison of Macular and Choroidal Thickness After Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis Recruiting NCT03363295 Phase 4 Moxifloxacin Injection
7 Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery Unknown status NCT01820520 Phase 3 brilliant blue G
8 A Randomized Study Comparing Brilliant Blue and Indocyanine Green as Intravitreal Dye in Macular Pucker and Macular Hole Unknown status NCT01083004 Phase 3
9 Ozurdex in Treatment of Macular Edema Post Membrane Peeling Completed NCT01273727 Phase 2, Phase 3 Dexamethasone;dexamethasone
10 A Descriptive Study to Evaluate the Effectiveness of the Dye Compound of the Combination of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy Completed NCT01627977 Phase 3
11 Vitreous pge2 Level Changes After Topical Administration of Diclofenac 0.1%, Nepafenac 0.3%, Indomethacin 0.5% and Bromfenac 0.09% in Vitrectomy Patients Completed NCT03597867 Phase 3 Dicloftil;Nevanac;Indom;Yellox
12 Randomized Clinical Trial of Cryotherapy Versus Postoperative Laser Photocoagulation for Retinopexy in Scleral Buckle Surgery Completed NCT01068379 Phase 3
13 Infliximab for Diabetic Macular Edema Refractory to Laser Photocoagulation: a Randomized, Double-Masked, Placebo-Controlled, Cross-Over, 32 Weeks Study Terminated NCT00505947 Phase 3 infliximab;placebo
14 Pars Plana Vitrectomy for Diabetic Fibrovascular Proliferation With and Without Internal Limiting Membrane Peeling Unknown status NCT00556244 Phase 1, Phase 2
15 Phase 2 Study of OT-551 Ophthalmic Solution to Prevent or Delay Progression of Nuclear Cataract Formation In Post-Vitrectomy Patients Terminated NCT00333060 Phase 2 OT-551 ophthalmic solution
16 A Prospective, Multi-Center, Single-Dose, Phase 1 Clinical Trial Designed to Evaluate the Pharmacokinetics of Dexamethasone Phosphate Ophthalmic Solution Delivered Via the EyeGate® II Drug Delivery System in Patients Undergoing Vitrectomy for Macular Hole Repair or Epiretinal Membrane Peeling Completed NCT02644694 Phase 1 Dexamethasone Phosphate Ophthalmic Solution
17 Phase I Study of Sequestered Transscleral, Controlled-Release Celecoxib Delivered Via Episcleral Reservoir for Treatment of Macular Edema & Inflammatory Disorders of the Eye Posterior Pole Including Sclera, Choroid, Retina or Vitreous Recruiting NCT04120636 Phase 1 Episcleral Celecoxib
18 Phase I Study of Sequestered Transscleral, Controlled-Release Dexamethasone Delivered Via Episcleral Reservoir for Treatment of Macular Edema & Inflammatory Disorders of the Eye Posterior Pole Including Sclera, Choroid, Retina or Vitreous Recruiting NCT04120311 Phase 1 Episcleral Dexamethasone
19 Change in Foveal Avascular Zone After Removal of Epiretinal Membrane and Internal Limiting Membrane Unknown status NCT01985490
20 Anatomic and Functional Outcomes of 23-gauge Vitrectomy Combined With Posterior Subtenon Triamcinolone Injection for the Treatment of Idiopathic Epiretinal Membrane Unknown status NCT01630876
21 A Prospective Multicentre Pilot Study of the Effectiveness of an Intra-operative Intravitreal Sustained Release Dexamethasone Implant (Ozurdex®) in Vitrectomy Surgery for Epiretinal Membranes Unknown status NCT01701518 Ozurdex
22 Comparison of Postoperative Aqueous Flare After 20G Versus 23G Pars Plana Vitrectomy Unknown status NCT01969929
23 Observational Prospective Monocentric Study Evaluating "Sweeper" Use During Epiretinal Membrane Surgery Unknown status NCT03350607
24 Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel. Unknown status NCT00892619
25 Gene Expression and Their Correlations in Patients With Idiopathic and Secondary Epiretinal Membranes in Proliferative Diabetic Retinopathy Unknown status NCT01946451
26 Robotic Retinal Dissection Device Trial Unknown status NCT03052881
27 Evaluation Use Optical Coherence Tomography - Rescan During Dissection of Macular Membranes : Pre and Post Operative Aspects Unknown status NCT02748421
28 Double Endotamponade With Perfluorodecalin and Silicone Oil in Retinal Detachment Surgery: Randomised Clinical Trial of Safety Unknown status NCT01959568
29 Virtual Vitreoretinal Surgery: Construction of a Training Program and Analysis of Significant Factors for Operating Performance Unknown status NCT02559661
30 Retinal Sensitivity and Optical Coherence Tomography Findings in Eyes With Idiopathic Epiretinal Membrane Completed NCT01481987
31 Correlation of Postoperative Vision and Fundus Autofluorescence After Vitrectomy for Epiretinal Membrane Completed NCT02628158
32 Change of Retinally-Induced Aniseikonia in Patients With Epiretinal Membrane After Vitrectomy Completed NCT01901406
33 Surgical Removal of Idiopathic Epiretinal Membrane With and Without the Assistance of Indocyanine Green: a Randomised Controlled Clinical Trial Completed NCT00376857 Surgery with and without the aid of Indocyanine Green (ICG)
34 "Retinal Thickness Change Following Cataract Surgery in Eyes With Epiretinal Membrane" Completed NCT03404323
35 Mid-term Clinical Assessment and Correlation Between Metamorphopsia, Visual Acuity and Foveal Thickness in Idiopathic Epiretinal Membrane and Cataract Surgery Completed NCT03045367
36 Study of the Impact of Air Versus SF6 20% on Visual Acuity Improvement After Epiretinal Membrane Stripping Completed NCT02030262
37 A Placebo-controlled, Randomized, Clinical Trial of Prophylactic Ketorolac 0.5% in Patients Undergoing Pars Plana Vitrectomy and Phacovitrectomy Epiretinal Membrane Peel Surgery: Assessing Macular Volume With Spectral-domain OCT Completed NCT00974753 Ketorolac 0.5%
38 Membranepeeling With Trypan Blue Versus Membranpeeling With Brillant Blue for Patients With Idiopathic Epiretinal Membranes Completed NCT00757380
39 A Prospective Pilot Study of Lucentis for Epiretinal Membranes: the LERM Study Completed NCT01238393 intravitreal ranibizumab
40 Visual and Anatomic Outcomes of Intravitreal Anti-VEGF Therapy for Exudative Age-related Macular Degeneration With Concurrent Significant Epiretinal Membrane. Completed NCT01846351
41 Assessment of Retinal Layers and Visual Rehabilitation After Epiretinal Membrane Removal Completed NCT01474655
42 Evaluation of the Cone Outer Segment Tips Line After Epiretinal Membrane Surgery Completed NCT01549249
43 Topical Use of Corticosteroid to Prevent Epiretinal Membrane Formation in Eyes With Retinal Tear Undergoing Laser Retinopexy: a Pilot Prospective Clinical Study Completed NCT02412059 Prednisolone acetate
44 Preoperative Prognostic Factors and Predictive Score in Patients Operated on for Combined Cataract and Idiopathic Epiretinal Membrane. Completed NCT02406430
45 To Peel or Not to Peel: Surgical Outcome of Macular Membrane Peeling Associated With Significant Macular Drusen Completed NCT03927430
46 Comparison of Macular Function and Visual Fields After Membrane Blue or Infracyanine Green Staining in Vitreoretinal Surgery Completed NCT00555269
47 Refractive Consequences of Epiretinal Membrane Surgery Completed NCT02413619
48 Macular Peeling With Foveal Sparing of the Internal Limiting Membrane: A Pilot Study Completed NCT03488576
49 Comparison of a Spectral OCT/SLO With the Stratus OCT for Imaging Various Retinal Pathologies Completed NCT00408720
50 Inner Nuclear Macular Microcyst is a Risk Factor for Macular Cystoid Changes After Phacoemulsification in Eyes With Previous Vitrectomy and Macular Pucker Removal Completed NCT03934190

Search NIH Clinical Center for Preretinal Fibrosis

Cochrane evidence based reviews: epiretinal membrane

Genetic Tests for Preretinal Fibrosis

Anatomical Context for Preretinal Fibrosis

MalaCards organs/tissues related to Preretinal Fibrosis:

40
Eye, Retina, Endothelial, Heart, Skin, Breast, Tongue

Publications for Preretinal Fibrosis

Articles related to Preretinal Fibrosis:

(show top 50) (show all 87)
# Title Authors PMID Year
1
Filigree Vascular Pattern in Combined Hamartoma of Retina and Retinal Pigment Epithelium on OCT Angiography. 61
31229419 2019
2
Peripapillary Versus Macular Combined Hamartoma of the Retina and Retinal Pigment Epithelium: Imaging Characteristics. 61
30689986 2019
3
Familial Exudative Retinopathy: A Case and Family Analysis. 61
30202620 2018
4
Clinical features and treatment outcomes of vasoproliferative tumors in Indian participants. 61
29380768 2018
5
Characteristics, demographics, outcomes, and complications of diabetic traction retinal detachments treated with silicone oil tamponade. 61
26916551 2016
6
[Preretinal hemorrhage and prognosis following vitrectomy and silicone oil tamponade for severe proliferative diabetic retinopathy]. 61
26038135 2015
7
Terson syndrome and leukemia: a case report. 61
24729684 2014
8
[Early treatment with Nd:YAG laser for Valsalva retinopathy: results of five cases and literature review]. 61
23618730 2013
9
Incidence and progression of epiretinal membranes in eyes after cataract surgery. 61
23628353 2013
10
Distribution, reabsorption, and complications of preretinal blood under silicone oil after vitrectomy for severe proliferative diabetic retinopathy. 61
22222267 2012
11
Transcription factor, SP1, in epiretinal membranes of patients with proliferative diabetic retinopathy. 54
20047772 2010
12
Expression of advanced glycation end products and related molecules in diabetic fibrovascular epiretinal membranes. 54
20447102 2010
13
Ratio of the vitreous vascular endothelial growth factor and pigment epithelial-derived factor in Eales disease. 54
20072643 2009
14
Different expression of vascular endothelial growth factor and pigment epithelium-derived factor between diabetic and non-diabetic epiretinal membranes. 54
19182495 2009
15
Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes. 54
18952655 2008
16
Changes of vascular endothelial growth factor after vitrectomy for macular edema secondary to retinal vein occlusion. 54
18988180 2008
17
Ganglion cell neurites in human idiopathic epiretinal membranes. 54
18577651 2008
18
Macular neovascularization in familial exudative vitreoretinopathy. 61
25390602 2008
19
Stromal-derived factor-1 and inflammatory cytokines in retinal vein occlusion. 54
18085471 2007
20
Morphologically functional correlations of macular pathology connected with epiretinal membrane formation in spectral optical coherence tomography (SOCT). 61
17479277 2007
21
Expression of hypoxia-inducible factor-1alpha and the protein products of its target genes in diabetic fibrovascular epiretinal membranes. 54
17229797 2007
22
Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders. 54
17375263 2007
23
Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy. 54
16531976 2007
24
Bilateral epiretinal membranes in Gorlin syndrome associated with a novel PTCH mutation. 54
17258529 2007
25
Intraretinal and periretinal pathology in anterior proliferative vitreoretinopathy. 54
16612635 2007
26
[Photodynamic therapy of circumscribed choroidal hemangiomas]. 61
17114994 2006
27
Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye. 54
17030714 2006
28
Expression of HB-EGF by retinal pigment epithelial cells in vitreoretinal proliferative disease. 54
17050278 2006
29
Vitreoretinal complications of retinoblastoma treatment. 61
16946679 2006
30
Intravitreous hepatocyte growth factor in patients with proliferative diabetic retinopathy: a case-control study. 54
16029908 2006
31
Expression of glutamine synthetase and cell proliferation in human idiopathic epiretinal membrane. 54
16361676 2006
32
Changes in retinal gene expression in proliferative vitreoretinopathy: glial cell expression of HB-EGF. 54
15988409 2005
33
Hyperconvolution of the inner limiting membrane in vitreomaculopathies. 54
15480733 2004
34
Glial cell expression of hepatocyte growth factor in vitreoretinal proliferative disease. 54
15156160 2004
35
Transpupillary thermotherapy in the management of circumscribed choroidal hemangioma. 61
15110668 2004
36
Possible benefits of triamcinolone-assisted pars plana vitrectomy for retinal diseases. 61
14707824 2003
37
Abnormalities of the vitreoretinal interface caused by dysregulated Hedgehog signaling during retinal development. 54
14570707 2003
38
Tenascin-C levels in the vitreous of patients with proliferative vitreoretinopathy. 54
14573976 2003
39
Idiopathic epiretinal membranes: cell type, growth factor expression, and fluorescein angiographic and retinal photographic correlations. 54
14620032 2003
40
Surgical management of retinal detachment secondary to acute retinal necrosis: clinical features, surgical techniques, and long-term results. 61
12967865 2003
41
Diabetic patients and retinal proliferation: an evaluation of the role of vascular endothelial growth factor (VEGF). 54
12845559 2003
42
Long-term follow-up of a modified technique for laser-induced chorioretinal venous anastomosis in nonischemic central retinal vein occlusion. 61
12750095 2003
43
[Detection of C5a receptor expressions on human epiretinal membranes and cultured RPE cells by immunohistochemical staining]. 54
15155075 2003
44
Outcome of vitreous surgery and the balance between vascular endothelial growth factor and endostatin. 54
12601027 2003
45
Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization. 54
12506101 2003
46
The role of matricellular proteins thrombospondin-1 and osteonectin during RPE cell migration in proliferative vitreoretinopathy. 54
12658547 2002
47
[Vitrectomy in treatment of idiopathic and secondary pre-retinal fibrosis]. 61
12046304 2002
48
Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy. 54
11004090 2000
49
Active scatter factor (HGF/SF) in proliferative vitreoretinal disease. 54
10967068 2000
50
Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative diabetic retinopathy. 54
10837392 2000

Variations for Preretinal Fibrosis

Expression for Preretinal Fibrosis

Search GEO for disease gene expression data for Preretinal Fibrosis.

Pathways for Preretinal Fibrosis

GO Terms for Preretinal Fibrosis

Cellular components related to Preretinal Fibrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 VEGFA TGFB2 HGF FN1 DPT ANGPT2
2 platelet alpha granule lumen GO:0031093 8.92 VEGFA TGFB2 HGF FN1

Biological processes related to Preretinal Fibrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.5 VEGFA TGFB2 ANGPT2
2 positive regulation of angiogenesis GO:0045766 9.43 VEGFA HGF ANGPT2
3 epithelial to mesenchymal transition GO:0001837 9.37 TGFB2 HGF
4 response to wounding GO:0009611 9.33 TGFB2 GFAP FN1
5 angiogenesis GO:0001525 9.26 VEGFA TGFB2 FN1 ANGPT2
6 platelet degranulation GO:0002576 8.92 VEGFA TGFB2 HGF FN1

Molecular functions related to Preretinal Fibrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemoattractant activity GO:0042056 9.16 VEGFA HGF
2 heparin binding GO:0008201 9.13 VEGFA LRTM2 FN1
3 growth factor activity GO:0008083 8.8 VEGFA TGFB2 HGF

Sources for Preretinal Fibrosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....